Imipenem/Cilastatin Actavis (Cilastatin Sodium, Imipenem Monohydrate)

Imipenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, disrupting peptidoglycan cross‑linking and causing cell lysis. Cilastatin is added to inhibit renal dehydropeptidase I, an enzyme that would otherwise degrade imipenem, thereby preserving its plasma concentration and antibacterial activity.

The exact dose and infusion rate are determined by the prescribing clinician based on the infection type, severity, patient weight, age, and renal function. Dosing regimens are individualized and should follow the latest clinical guidelines and the product’s prescribing information.

Imipenem/Cilastatin is classified as pregnancy category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used during pregnancy when the potential benefit justifies the risk. Limited data are available for breastfeeding; the decision should be made by a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Imipenem/Cilastatin offers a broad spectrum similar to other carbapenems such as meropenem or ertapenem, but its combination with cilastatin protects the drug from renal degradation, allowing higher plasma levels. Choice among carbapenems depends on local resistance patterns, pharmacokinetic considerations, and specific patient factors.

The product should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Reconstituted solutions are generally stable for a limited period at room temperature; always follow the manufacturer’s instructions for preparation and use.

Imipenem/Cilastatin is supplied as a powder for solution for injection and is administered intravenously. The reconstituted solution is infused over a specified period, typically 30 minutes, under aseptic conditions. Administration details, including infusion rate, are determined by the prescriber.

Serious adverse events include seizures, especially in patients with renal impairment or pre‑existing CNS disorders, severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and significant renal toxicity. Prompt recognition and medical intervention are essential if these events occur.

Patients with a known hypersensitivity to imipenem, cilastatin, or any component of the formulation should avoid the drug. Caution is also advised for individuals with a history of seizures, severe renal impairment, or those receiving valproic acid, unless the benefits outweigh the risks.